3,4-Methylenedioxyphentermine (MDPH) is a lesser-known drug of the amphetamine family. MDPH was first synthesized by Alexander Shulgin. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.
![]() | |
Names | |
---|---|
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-2-methylpropan-2-amine | |
Other names
MDP; MDPH; 3,4-Methylenedioxyphentermine;
3,4-Methylenedioxy-alpha,alpha-dimethyl-1-ethane | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C11H15NO2 | |
Molar mass | 193.246 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
In his book PiHKAL (Phenethylamines i Have Known And Loved), the dosage range is listed as 160–240 mg, and the duration as 3–5 hours.[1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D.
The N-methyl derivative, 3,4-methylenedioxy-N-methylphentermine (MDMPH), has been described by Shulgin as lacking MDMA-like effects.[2] Accordingly, MDMPH, as well as MDPH, were found to be inactive as serotonin releasing agents in vitro.[2][3]
Legality
editUnited Kingdom
editThis substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]
See also
editReferences
edit- ^ MDPH entry in PiHKAL
- ^ a b Nichols, David F.; Oberlender, Robert (1990). "Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?". Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Vol. 9. Boston, MA: Springer US. p. 105–131. doi:10.1007/978-1-4613-1485-1_7. ISBN 978-1-4612-8799-5.
- ^ Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (May 1982). "Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes". J Med Chem. 25 (5): 530–535. doi:10.1021/jm00347a010. PMID 7086839.
- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.